Ligand Pharmaceuticals | LGND - Loan Capital


Ligand Pharmaceuticals reported $446.19M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Agenus USD 169.66M 146.06M Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Baxter International USD 8.62B 852M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Enviri Corporation USD 1.56B 26.44M Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 542.22M 1.25M Mar/2026
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 46.67B 77M Mar/2026
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 0 0 Mar/2025